 |
市場調查報告書
商品編碼
2075196
青光眼眼藥水市場：依藥物類型、適應症、通路、活性成分及地區分類。Glaucoma Eye Drops Market, by Drug Type, by Disease Indication, By Distribution Channel, by Composition, and by Region |
||||||
價格
簡介目錄
預計到2026年，青光眼眼藥水市場規模將達到20.62億美元，到2033年將達到34.209億美元。預計從2026年到2033年，其複合年成長率將達到7.5%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 20.62億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 7.50% | 2033年市場規模預測： | 34.209億美元 |
青光眼是一組眼科疾病，會傷害位於眼球後方的視神經，導致視力喪失甚至失明。青光眼的症狀通常出現緩慢，患者可能甚至沒有意識到自己患有青光眼。目前，檢查青光眼的唯一方法是進行全面的散瞳眼科檢查。無論是否患有糖尿病，都可能發生青光眼。此外，糖尿病視網膜病變患者罹患青光眼的風險更高。糖尿病視網膜病變與異常血管增生有關，這些血管會導致視網膜病變並阻塞眼內正常的房水排出通道。老年人口的快速成長是青光眼盛行率上升的關鍵因素之一，預計這將推動青光眼治療市場在不久的將來成長。
市場動態
受青光眼盛行率不斷上升的推動，預計全球青光眼眼藥水市場在預測期內將顯著成長。例如，根據美國疾病管制與預防中心（CDC）的數據，截至2020年11月，美國約有300萬人因青光眼失明。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數對全球青光眼眼藥水市場的主要參與者進行了分析：公司概況、財務表現、產品系列、企業發展區域、分銷策略、關鍵發展和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、政府政策、技術升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球青光眼眼藥水市場報告」相關人員、研究和諮詢公司、新參與企業和金融分析師。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第3章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第5章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 經濟影響
- 對供需的影響
第8章 全球青光眼眼藥水市場：依藥物類型分類，2021-2033年
- 前列腺素類似物
- BETA阻斷劑
- α受體促效劑
- 碳酸酐酶抑制劑（CAIs）
- 複方製劑
- 其他
第10章 全球青光眼眼藥水市場：依疾病分類，2021-2033年
- 隅角閉鎖性青光眼
- 開放性青光眼
第12章 全球青光眼眼藥水市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第14章 全球青光眼眼藥水市場：依成分分類，2021-2033年
- 不含防腐劑
- BAK型
- 除苯扎氯銨（BAK）類防腐劑以外的其他防腐劑
第16章 全球青光眼眼藥水市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第17章 競爭格局
- Merck KGaA
- Allergan plc（A subsidiary of AbbVie Inc）
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Bausch & Lomb
- Inotek
- Jadran-galenski laboratorij dd（JGL dd）
- Aerie Pharmaceutical（A subsidiary of Alcon Management S. A）
- Mylan NV（A subsidiary of Viatris Inc.）
第18章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI3984
Glaucoma Eye Drops Market is estimated to be valued at USD 2,062.0 Mn in 2026 and is expected to reach USD 3,420.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,062.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 3,420.9 Mn |
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of your eye called the optic nerve. The symptoms can start so slowly that a patient may not notice them. The only way to find out if a person has glaucoma is to get a comprehensive dilated eye exam. Glaucoma may occur among people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for the increasing prevalence of glaucoma, which in turn is projected to drive the growth of the glaucoma therapeutics market in the near future.
Market Dynamics
The global glaucoma eye drops market is expected to witness significant growth during the forecast period owing to the increasing prevalence of glaucoma. For instance, according to the Centre for Disease Control and Prevention, in November 2020, an estimated 3 Mn people suffered from blindness due to glaucoma in the U.S. 2020.
Key features of the study:
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global glaucoma eye drops market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.)
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics.
- The global glaucoma eye drops market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for glaucoma eye drops, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Glaucoma Eye Drops Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
- Prostaglandin analogs
- Beta blockers
- Alpha agonists
- Carbonic Anhydrase Inhibitors (CAIs)
- Combined Medications
- Others (rho-kinase inhibitor, Cholinergic agonist)
- Global Glaucoma Eye Drops Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
- Angle-closure Glaucoma
- Open-angle Glaucoma
- Global Glaucoma Eye Drops Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Glaucoma Eye Drops Market, By Composition (Revenue, USD Mn, 2021 - 2033)
- Preservative Free
- BAK-Based
- Non BAK-Based Preservatives
- Global Glaucoma Eye Drops Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck KGaA
- Allergan plc ( A subsidiary of AbbVie Inc)
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Bausch & Lomb
- Inotek
- Jadran-galenski laboratorij d.d. JGL d.d
- Aerie Pharmaceutical (A subsidiary of Alcon Management S. A)
- Mylan N.V. (A subsidiary of Viatris Inc.)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
3. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Composition
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
5. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Economic Impact
- Impact on Supply and Demand
8. Global Glaucoma Eye Drops Market, By Drug Type, 2021€"2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Prostaglandin analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Beta blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Alpha agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Carbonic Anhydrase Inhibitors (CAIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Combined Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
10. Global Glaucoma Eye Drops Market, By Disease Indication, 2021€"2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Angle-closure Glaucoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Open-angle Glaucoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
12. Global Glaucoma Eye Drops Market, By Distribution Channel, 2021€"2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
14. Global Glaucoma Eye Drops Market, By Composition, 2021€"2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Preservative Free
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- BAK-Based
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Non BAK-Based Preservatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
16. Global Glaucoma Eye Drops Market, By Region, 2021€"2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022€"2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €" 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Composition, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
17. Competitive Landscape
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Allergan plc ( A subsidiary of AbbVie Inc)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch & Lomb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Inotek
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jadran-galenski laboratorij d.d. (JGL d.d)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aerie Pharmaceutical (A subsidiary of Alcon Management S. A)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V. (A subsidiary of Viatris Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
18. Section
- Research Methodology
- About Us
